No Detail Found!

Engineering transferrin and epirubicin onto magnetic nanoparticles for targeting drug delivery through transferrin receptors.

Author(s)
Snober Ahmed Institute of Biochemistry and Biotechnology, University of the Punjab, Quaid-i- Azam Campus, Lahore, Pakistan
Zahoor Qadir Samra Institute of Biochemistry and Biotechnology, University of the Punjab, Quaid-i- Azam Campus, Lahore, Pakistan
Abstract
Cancer is a serious health problem worldwide. New nanomedicines are being developed for targeting drug delivery through receptor endocytosis process of the cell. The expression of transferrin receptors is increased in cancer cells. Transferrin and epirubicin were attached with magnetic nanoparticles (MNPs) to deliver anti-cancer drug at target site (in vitro). MagLISA was used to confirm the bindings of transferrin and epirubicin with MNPs by using anti-transferrin and antiepirubicin antibodies. The MNP-transferrin-epirubicin conjugates are stable in water and carbonate buffer. 10% to 11% drug was released at pH 7.4 and in human serum but 37% to 38% drug released was observed at pH 5.5. After 96 hours, comparatively more killing effect was observed on HeLa cells (14.7%) than on normal B cells (9.8%). The binding of conjugates with HeLa cells and B cells was observed 56.83% and 39.33% respectively. The binding was confirmed (in situ) by immunofluorescence and immunoperoxidase microscopy using anti-epirubicin and anti-transferrin antibodies respectively. HeLa cells and B-cells treated with anti-HeLa cells and anti-B-cells antibodies were devoid of peroxidase reaction product which indicated that the receptors were masked with antibodies. Transferrin-MNPs conjugates may be considered good for targeting drug delivery.
Publication Details
Page(s) 1117-1124
DOI DOI not available
Published Journal: Pakistan Journal of Zoology, Volume: 48, Issue: 4, Year: 2016

Request the full text from PASTIC

0

Citations

0

Downloads

63

Views